These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 2951357)

  • 1. Clinical development of nafarelin acetate. Phase I and phase II studies.
    Hoffman PG; Henzl MR; Chaplin MD; Nerenberg CA
    J Androl; 1987; 8(1):S17-22. PubMed ID: 2951357
    [No Abstract]   [Full Text] [Related]  

  • 2. Intranasal nafarelin: an LH-RH analogue treatment of gonadotropin-dependent precocious puberty.
    Lin TH; LePage ME; Henzl M; Kirkland JL
    J Pediatr; 1986 Dec; 109(6):954-8. PubMed ID: 2946840
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Results of a Dutch Phase II trial with the LHRH agonist buserelin in patients with metastatic prostatic cancer.
    Debruyne FM; Karthaus HF; Schröder FH; de Voogt HJ; de Jong FH; Klijn JG
    Prog Clin Biol Res; 1985; 185A():251-70. PubMed ID: 3929265
    [No Abstract]   [Full Text] [Related]  

  • 4. A review of the pharmacokinetic and pharmacological properties of a once-yearly administered histrelin acetate implant in the treatment of prostate cancer.
    Schlegel P
    BJU Int; 2009 Mar; 103 Suppl 2():7-13. PubMed ID: 19228147
    [No Abstract]   [Full Text] [Related]  

  • 5. Pharmaceutical aspects. Nasal and depot formulations of leuprolide.
    Shimamoto T
    J Androl; 1987; 8(1):S14-6. PubMed ID: 3104262
    [No Abstract]   [Full Text] [Related]  

  • 6. Metastatic prostate cancer under long term pernasal buserelin or intramuscular decapeptyl depot treatment.
    Wenderoth UK; Spindler HW; Ehrenthal W; von Wallenberg H; Happ J; Jacobi GH
    Prog Clin Biol Res; 1987; 243A():207-20. PubMed ID: 2958851
    [No Abstract]   [Full Text] [Related]  

  • 7. Nafarelin controlled release injectable: theoretical clinical plasma profiles from multiple dosing and from mixtures of microspheres containing 2 per cent, 4 per cent and 7 per cent nafarelin.
    Burns RA; Vitale K; Sanders LM
    J Microencapsul; 1990; 7(3):397-413. PubMed ID: 2143531
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Consensus statement on the use of gonadotropin-releasing hormone analogs in children.
    Carel JC; Eugster EA; Rogol A; Ghizzoni L; Palmert MR; ; Antoniazzi F; Berenbaum S; Bourguignon JP; Chrousos GP; Coste J; Deal S; de Vries L; Foster C; Heger S; Holland J; Jahnukainen K; Juul A; Kaplowitz P; Lahlou N; Lee MM; Lee P; Merke DP; Neely EK; Oostdijk W; Phillip M; Rosenfield RL; Shulman D; Styne D; Tauber M; Wit JM
    Pediatrics; 2009 Apr; 123(4):e752-62. PubMed ID: 19332438
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative disposition of nafarelin and endogenous luteinizing hormone releasing hormone in female rats.
    Hama KM; Chu NI; Chan RL; Chaplin MD
    Proc West Pharmacol Soc; 1984; 27():303-6. PubMed ID: 6238335
    [No Abstract]   [Full Text] [Related]  

  • 10. [Treatment of prostatic cancer with slow-release formulation of luteinizing hormone releasing hormone (LH-RH) analog].
    Fuse H; Akimoto S; Akakura K; Shimazaki J; Murakami S
    Hinyokika Kiyo; 1988 Mar; 34(3):555-60. PubMed ID: 3133936
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gonadotropin-releasing hormone agonists. Current uses for these increasingly important drugs.
    Winkel CA
    Postgrad Med; 1994 May; 95(6):111-8. PubMed ID: 8170869
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nafarelin for endometriosis.
    Med Lett Drugs Ther; 1990 Aug; 32(825):81-2. PubMed ID: 2143265
    [No Abstract]   [Full Text] [Related]  

  • 13. Experience in the use of nafarelin for treatment of benign breast disease.
    Roberts JV
    Br J Clin Pract Suppl; 1989 Nov; 68():37-42; discussion 49-53. PubMed ID: 2535115
    [No Abstract]   [Full Text] [Related]  

  • 14. Phase III studies in prostatic cancer with leuprolide acetate.
    Seely JH
    J Androl; 1987; 8(1):S23-6. PubMed ID: 3104263
    [No Abstract]   [Full Text] [Related]  

  • 15. Nafarelin: a new medical therapy for endometriosis.
    Henzl MR; Monroe SE
    Prog Clin Biol Res; 1990; 323():343-55. PubMed ID: 2137620
    [No Abstract]   [Full Text] [Related]  

  • 16. [Homologues of gonadotropin releasing factors].
    Agostino A; Simeoni A; Altomonte G; Jacobelli A
    Clin Ter; 1987 Mar; 120(5):427-32. PubMed ID: 2953542
    [No Abstract]   [Full Text] [Related]  

  • 17. [Treatment with D-Trp-6-LHRH. Plasma levels and gonadotropic response].
    Lahlou N; Duchier J; Feinstein MC; Mauvernay RY; Roger M; Schally AV
    Pathol Biol (Paris); 1984 Oct; 32(8):906-8. PubMed ID: 6209605
    [No Abstract]   [Full Text] [Related]  

  • 18. Selection of children with precocious puberty for treatment with gonadotropin releasing hormone analogs.
    Rosenfield RL
    J Pediatr; 1994 Jun; 124(6):989-91. PubMed ID: 8201493
    [No Abstract]   [Full Text] [Related]  

  • 19. [Management of true precocious puberty with a delayed-action Gn-RH analog].
    Julesz J; Iványi T; Domokos I; Janáky T; Faredin I; László F
    Orv Hetil; 1986 Dec; 127(49):3005-9. PubMed ID: 3099244
    [No Abstract]   [Full Text] [Related]  

  • 20. Bioavailability of nafarelin in healthy volunteers.
    Chaplin MD
    Am J Obstet Gynecol; 1992 Feb; 166(2):762-5. PubMed ID: 1531580
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.